LUND, SWEDEN--(Marketwire - August 10, 2012) -
* Laquinimod - application submitted for regulatory approval in the EU resulting in milestone payment of USD 5 M during third quarter 2012 - a Phase III study will be initiated in the US
* TASQ - milestone payment of EUR 10 M received from Ipsen in connection with meeting patient enrolment target for Phase III study - overall survival data from Phase II study presented
* ANYARA - Phase III trial continuing according to plan
* 57-57 - a clinical trial in systemic sclerosis/scleroderma in progress
* ISI - project proceeding as planned
* The organization has been adapted to the company’s new direction
* Net sales: SEK 96.6 M (228.8)
* Operating loss: SEK 120.6 M (profit: 70.6)
* Loss after tax: SEK 123.5 M (profit: 77.7)
* Loss per share for the period: SEK 1.79 (earnings: 1.14)
This report is also available at www.activebiotech.com
Fax: +46 (0)46 19 11 00
Active Biotech AB Interim report Jan - June 2012: http://hugin.info/1002/R/1633117/523993.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1633117]
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam
CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
